Delivery Order SPE2DR25D9367-SPE2DR26FKKH3
- Not listed
- The Defense Logistics Agency awarded a $36,976.24 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count unit dose packaging). The delivery order, issued on November 5, 2025, with an ultimate completion date of November 6, 2025, carries no set-aside designation, indicating the award was made through full and open competition. DMS...
- The Defense Logistics Agency awarded a delivery order valued at $79,695.84 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). The award, issued on November 10, 2025, with an ultimate completion date of November 12, 2025, utilizes firm fixed-price pricing and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $56,604.96 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). The delivery order, issued on December 12, 2025, with an ultimate completion date of December 15, 2025, was awarded without a set-aside designation, reflecting the contractor's competitive capability in unrestricted...
- The Defense Logistics Agency has awarded a delivery order valued at $18,868.32 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). This firm fixed-price delivery order, issued on December 3, 2025, with an ultimate completion date of December 4, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted...
- The Defense Logistics Agency issued a delivery order valued at $37,736.66 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). This firm fixed-price delivery order, awarded on December 5, 2025, with an ultimate completion date of December 8, 2025, was issued without a set-aside designation, reflecting the contractor's competitive capability in unrestricted...
- The Defense Logistics Agency issued a $95,242.06 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). The award, issued on November 28, 2025, with an ultimate completion date of December 1, 2025, represents a routine pharmaceutical delivery under the agency's medical supply operations. DMS Pharmaceutical Group was selected...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $18,868.32 to DMS Pharmaceutical Group Inc. on December 16, 2025, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected through a firm fixed-price contract with no set-aside designation, demonstrating the company's competitive capability in unrestricted federal...
- The Defense Logistics Agency issued a $56,604.96 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for Trikafta 100-50-75 mg/150 mg tablets (84-count units). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, is the sole awardee with no identified subcontractors. The delivery order was awarded on December 15, 2025, with an ultimate completion date of December 16, 2025, and was issued without a set-aside designation,...
- The Defense Logistics Agency awarded a $37,722.26 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). This delivery order, issued on December 8, 2025, with an ultimate completion date of December 9, 2025, represents a routine pharmaceutical procurement under DLA's Medical Supply Chain operations. No set-aside designation...
- The Defense Logistics Agency awarded a delivery order valued at $18,488.12 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets. This firm fixed-price delivery order, issued on October 29, 2025, with an ultimate completion date of October 30, 2025, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. DMS Pharmaceutical Group...
- SPE2DR25D9367Indefinite Delivery Contract
- SPE2DR25D9367-SPE2DR26FKKH3Delivery Order
The Defense Logistics Agency awarded a $56,604.96 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). The delivery order, issued on December 18, 2025, with an ultimate completion date of December 19, 2025, carries no set-aside designation and was awarded competitively under the company's existing Indefinite Delivery Contract with DLA. DMS Pharmaceutical Group Inc. serves as a critical supplier within the Department of Defense's pharmaceutical supply chain and has demonstrated consistent performance across multiple therapeutic categories and product lines. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy. The underlying IDC, designated SPE2DR and awarded on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. This contract vehicle authorizes DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables, to support recurring medical supply needs of Department of Defense healthcare facilities worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $56.6k | 12/17/25 |